Kazia Therapeutics: New Indications For GDC-0084
Edison | Oct 29, 2018 06:24AM ET
Kazia Therapeutics Ltd (AX:KZA) has added two further indications to the development programme for its brain-penetrant PI3K inhibitor GDC-0084 through collaborations with prestigious US-based cancer centres. The collaborations further validate the potential of GDC-0084, which was in-licensed from Genentech in 2016. Importantly, the two additional indications will provide alternative pathways to a potential first marketing approval for GDC-0084, increasing the overall likelihood of success. Kazia’s ongoing Phase IIa study of GDC-0084 in glioblastoma (GBM) is expected to report first data in early 2019. Kazia raised A$3.4m through a recent share placement and has a share purchase plan (SPP) underway to raise additional funds. We increase our valuation range to between A$83m and A$139m.
Breast cancer brain metastases with Dana-Farber
The first collaboration is with the Dana-Farber Cancer Institute to investigate GDC-0084 in combination with Herceptin in women with HER2-positive breast cancer who have developed brain metastases. We had already included this potential indication in our valuation model for GDC-0084, so we are pleased to see that a trial will soon be underway. Genentech showed that GDC-0084 improves survival in this indication in animal studies, and a successful Phase III study for Novartis’s BYL719 validates targeting PI3K in breast cancer.
To read the entire report Please click on the pdf File Below..
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.